Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Phathom Pharmaceuticals Inc
(NQ:
PHAT
)
9.480
-0.320 (-3.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
421,170
Open
9.680
Bid (Size)
9.380 (2)
Ask (Size)
10.47 (1)
Prev. Close
9.800
Today's Range
9.450 - 9.820
52wk Range
6.065 - 17.02
Shares Outstanding
43,614,075
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
March 26, 2024
National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive...
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Performance
YTD
+3.38%
+3.38%
1 Month
+14.49%
+14.49%
3 Month
+25.56%
+25.56%
6 Month
+7.60%
+7.60%
1 Year
-4.63%
-4.63%
More News
Read More
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
March 07, 2024
Via
InvestorPlace
Preview: Phathom Pharmaceuticals's Earnings
March 06, 2024
Via
Benzinga
Recap: Phathom Pharmaceuticals Q3 Earnings
November 09, 2023
Via
Benzinga
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
February 29, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
February 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Earnings Scheduled For March 7, 2024
March 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 16, 2024
Via
Benzinga
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
February 13, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
Phathom Pharmaceuticals
Via
GlobeNewswire
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
January 05, 2024
Via
Benzinga
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
December 14, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
December 06, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
November 28, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
November 09, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 01, 2023
Via
Benzinga
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
November 01, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
What's Going On With Phathom Pharmaceuticals Stock?
October 30, 2023
Via
Benzinga
Exposures
Product Safety
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
October 30, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
October 25, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Cramer Likes This Industrial Stock: A 'Well-Run' Company Doing 'A Lot Of Good Things'
October 13, 2023
Via
Benzinga
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
September 26, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.